Non-bacterial infections in Asian patients treated with alemtuzumab: A retrospective study of the Asian Lymphoma Study Group

Leukemia and Lymphoma

Volumn 53, Issue 8, 2012, Pages 1515-1524

  Kim, Seok Jin ^a   Moon, Joon Ho ^b   Kim, Hawk ^c   Kim, Jin Seok ^d   Hwang, Yu Yan ^e   Intragumtornchai, Tanin ^f   Issaragrisil, Surapol ^g   Kwak, Jae Yong ^h   Lee, Je Jung ⁱ   Won, Jong Ho ^j   Reksodiputro, Arry Harryanto ^k   Lim, Soon Thye ^l   Cheng, Ann Lii ^m   Kim, Won Seog ^a   Kwong, Yok Lam ^e  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Kyungpook National University Hospital   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Yonsei University College of Medicine   (South Korea)

^e QUEEN MARY HOSPITAL   (Hong Kong)

^f CHULALONGKORN UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h Chonbuk National University Medical School   (South Korea)

ⁱ Chonnam National University Research Institute of Medical Sciences   (South Korea)

^j Soonchunhyang University College of Medicine   (South Korea)

^k CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^l DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^m NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

more..

Author keywords

Alemtuzumab; infection; prophylaxis

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; COTRIMOXAZOLE; FLUCONAZOLE; ITRACONAZOLE; VALACICLOVIR; VALGANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; APLASTIC ANEMIA; ARTICLE; ASIAN; CHILD; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG DOSE COMPARISON; FEMALE; HEPATITIS B VIRUS; HERPES ZOSTER; HUMAN; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOSIS; MYELODYSPLASTIC SYNDROME; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SIDE EFFECT; T CELL LYMPHOMA; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIA; CHILD; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HERPES ZOSTER; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84864245939     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.659735     Document Type: Article

References (40)

1. R odig SJ, Abramson JS, Pinkus GS, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006;12:7174-7179.
2. P iccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007;92:566-567.
3. S alisbury JR, Rapson NT, Codd JD, et al. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas. J Clin Pathol 1994;47:313-317.
4. R avandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Th er 2005;5:39-51.
5. K eating MJ, Flinn I, Jain V, et al. Th erapeutic role of alemtuzumab (Campath-1H) in patients who have failed fl udarabine: results of a large international study. Blood 2002;99:3554-3561.
6. H illmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as fi rst-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
7. G allamini A, Zaja F, Patti C, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as fi rst-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007;110:2316-2323.
8. K im JG, Sohn SK, Chae YS, et al. Alemtuzumab plus CHOP as frontline chemotherapy for patients with peripheral T-cell lymphomas: A phase II study. Cancer Chemother Pharmacol 2007;60:129-134.
9. E nblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004;103:2920-2924.
10. K im SJ, Kim K, Kim BS, et al. Alemtuzumab and DHAP (A-DHAP) is eff ective for relapsed peripheral T-cell lymphoma, unspecifi ed: interim results of a phase II prospective study. Ann Oncol 2009;20:390-392.
11. Morris E, Th omson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004;104:3865-3871.
12. Gomez-Almaguer D, Ruiz-Arguelles GJ, del Carmen Tarin-Arzaga L, et al. Alemtuzumab for the treatment of steroid-refractory acute graftversus- host disease. Biol Blood Marrow Transplant 2008;14:10-15.
13. Ruiz-Arguelles GJ, Gil-Beristain J, Magana M, et al. Alemtuzumabinduced resolution of refractory cutaneous chronic graft-versus-host disease. Biol Blood Marrow Transplant 2008;14:7-9.
14. Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as fi rst-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia 2004;18:484-490.
15. Rawstron AC, Kennedy B, Moreton P, et al. Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. Blood 2004;103:2027-2031.
16. Th ursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. Br J Haematol 2006;132:3-12.
17. Lim ZY, Cook G, Johnson PR, et al. Results of a phase I/II British Society of Bone Marrow Transplantation study on PCR-based preemptive therapy with valganciclovir or ganciclovir for active CMV infection following alemtuzumab-based reduced intensity allogeneic stem cell transplantation. Leuk Res 2009;33:244-249.
18. Orlandi EM, Baldanti F, Citro A, et al. Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fl udarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy. Haematologica 2008;93: 1758-1760.
19. Takeuchi T, Kameda H. Th e Japanese experience with biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2010;6:644-652.
20. N obre CA, Callado MR, Lima JR, et al. Tuberculosis infection in rheumatic patients with infl iximab therapy: experience with 157 patients. Rheumatol Int 2011 Aug 7. [Epub ahead of print]
21. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 2009;90:13-23.
22. Chae YS, Sohn SK, Kim JG, et al. Impact of alemtuzumab as conditioning regimen component on transplantation outcomes in case of CMV-seropositive recipients and donors. Am J Hematol 2008;83:649-653.
23. P ark SH, Choi SM, Lee DG, et al. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin. Transpl Infect Dis 2009;11:413-423.
24. Asano-Mori Y, Kanda Y, Oshima K, et al. Clinical features of late cytomegalovirus infection after hematopoietic stem cell transplantation. Int J Hematol 2008;87:310-318.
25. Kim H, Min YJ, Baek JH, et al. A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome. Leuk Res 2009;33:222-231.
26. K im SJ, Kim K, Park Y, et al. Dose modifi cation of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of effi cacy and toxicity. Invest New Drugs 2012;30:368-375.
27. C avalli-Bjorkman N, Osby E, Lundin J, et al. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fl udarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002;19:277-280.
28. A bruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodefi cient patients previously treated with fl udarabine for low-grade B-cell neoplasms. Am J Surg Pathol 2002;26:630-636.
29. O'Brien SM, Kantarjian HM, Th omas DA, et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003;98:2657-2663.
30. E lter T, Vehreschild JJ, Gribben J, et al. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab. Ann Hematol 2009;88:121-132.
31. S andherr M, Einsele H, Hebart H, et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006;17:1051-1059.
32. L aurenti L, Piccioni P, Cattani P, et al. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir. Haematologica 2004;89:1248-1252.
33. G ibbs SD, Herbert KE, McCormack C, et al. Alemtuzumab: eff ective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sezary syndrome. Eur J Haematol 2004;73:447-449.
34. Y eo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004;22:927-934.
35. Iannitto E, Minardi V, Calvaruso G, et al. Hepatitis B virus reactivation and alemtuzumab therapy. Eur J Haematol 2005;74:254-258.
36. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: A hidden menace? Hepatology 2001;34:204-206.
37. Brechot C, Th iers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically signifi cant or purely " occult "? Hepatology 2001;34:194-203.
38. K im SM, Lee KS, Park CJ, et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007;54:185-191.
39. Fabian I, Flidel O, Gadish M, et al. Eff ects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils. Exp Hematol 1993;21:1522-1527.
40. Au WY, Leung AY, Tse EW, et al. High incidence of tuberculosis after alemtuzumab treatment in Hong Kong Chinese patients. Leuk Res 2008;32:547-551.